Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Aug 9:6:465-72.
doi: 10.2147/vhrm.s6611.

Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia

Hugo Van Herendael  1 , Paul Dorian
Affiliations
Review

Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia

Hugo Van Herendael et al. Vasc Health Risk Manag. .

Abstract

Amiodarone has emerged as the leading antiarrhythmic therapy for termination and prevention of ventricular arrhythmia in different clinical settings because of its proven efficacy and safety. In patients with shock refractory out-of-hospital cardiac arrest and hemodynamically destabilizing ventricular arrhythmia, amiodarone is the most effective drug available to assist in resuscitation. Although the superiority of the transvenous implantable cardioverter defibrillator (ICD) over amiodarone has been well established in the preventive treatment of patients at high risk of life-threatening ventricular arrhythmias, amiodarone (if used with a beta-blocker) is the most effective antiarrhythmic drug to prevent ICD shocks and treat electrical storm. Both the pharmacokinetics and the electrophysiologic profile of amiodarone are complex, and its optimal and safe use requires careful patient surveillance with respect to potential adverse effects.

Keywords: amiodarone; unstable ventricular tachycardia; ventricular fibrillation.

PubMed Disclaimer

References

    1. Singh BN. Amiodarone: Historical development and pharmacologic profile. Am Heart J. 1983;106:788–797. - PubMed
    1. Van Schepdael J, Solvay H. Etude Clinique De L’Amiodarone Dans Les Troubles du Rhythme Cardiaque. Presse Med. 1970;78:1849. - PubMed
    1. Singh BN, Vaughan Williams EM. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol. 1970;39(4):657–667. - PMC - PubMed
    1. Rosenbaum MB, Chiale PA, Halpern MS, et al. Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol. 1976;38(7):934–944. - PubMed
    1. Connolly SJ. Evidence-Based Analysis of Amiodarone Efficacy and Safety. Circulation. 1999;100(19):2025–2034. - PubMed

MeSH terms